Chen Fengwu, He Lina, Li Jilin, Yang Shuhui, Zhang Bangzhou, Zhu Dan, Wu Zezhen, Zhang Shuo, Hou Ducheng, Ouyang Cong, Yi Jianfeng, Xiao Chuanxing, Hou Kaijian
The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Department of Endocrine and Metabolic Diseases, Longhu People's Hospital, Shantou, China.
Front Mol Biosci. 2022 Jun 15;9:879294. doi: 10.3389/fmolb.2022.879294. eCollection 2022.
To evaluate the protective effect of Polyethylene Glycol Loxenatide Injection (Glucagon-like peptide-1, GLP-1) on endothelial cells from middle-aged and elderly patients with newly diagnosed or poorly controlled type 2 diabetes mellitus (T2DM). GLP-1 weekly formulation was analyzed for cardiovascular disease protection and correlated with intestinal flora. Stool samples were collected from middle-aged and elderly patients with new-onset or poorly controlled type 2 diabetes in Longhu People's Hospital and Shantou Central Hospital from June 2019 to November 2019. Samples were collected at week 0, 4, and 8 of treatment with GLP-1 weekly formulations. Samples were analyzed for metagenomic sequencing. Analysis was performed to compare the characteristics of the gut microbiota at week 0, 4, and 8 of GLP-1 treatment and to correlate different microbiota with characteristic clinical parameters. Statistical differences were found in blood glucose lowering, cardiovascular endothelial, and inflammation-related indices between week 0 and W4 and in blood glucose lowering and cardiovascular endothelial indices from week 0 to 8 in the newly diagnosed or poorly controlled type 2 diabetic patients treated with GLP-1. Changes in gut microbiota at week 0, 4, and 8 after using GLP-1 were not statistically different, but had an overall trend of rising and then falling, and with different bacteria, that were correlated with different clinical indicators. GLP-1 improves endothelial cell function indicators in middle-aged and elderly diabetic patients, which may be related to its alteration of the population numbers of gut microbiota such as , , and . This study provides a guidance for the treatment of type 2 diabetic patients.
评估聚乙二醇洛塞那肽注射液（胰高血糖素样肽-1，GLP-1）对新诊断或血糖控制不佳的中老年2型糖尿病（T2DM）患者内皮细胞的保护作用。分析GLP-1每周制剂对心血管疾病的保护作用，并与肠道菌群进行关联分析。2019年6月至2019年11月，收集龙湖人民医院和汕头市中心医院新诊断或血糖控制不佳的中老年2型糖尿病患者的粪便样本。在使用GLP-1每周制剂治疗的第0、4和8周收集样本。对样本进行宏基因组测序分析。进行分析以比较GLP-1治疗第0、4和8周时肠道微生物群的特征，并将不同的微生物群与特征性临床参数进行关联。在新诊断或血糖控制不佳的2型糖尿病患者中，使用GLP-1治疗后，第0周和第4周之间在血糖降低、心血管内皮和炎症相关指标方面存在统计学差异，第0周和第8周之间在血糖降低和心血管内皮指标方面存在统计学差异。使用GLP-1后第0、4和8周肠道微生物群的变化无统计学差异，但总体呈先上升后下降趋势，且不同细菌与不同临床指标相关。GLP-1改善中老年糖尿病患者的内皮细胞功能指标，这可能与其改变如、和等肠道微生物群的种群数量有关。本研究为2型糖尿病患者的治疗提供了指导。
